However, the use of CTLA-4 for UC has been limited even though it is approved for use in the treatment of other highly mutagenic cancers, such as melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC). Here, CTLA4 is linked to melanoma.